BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
The FDA has approved Eli Lilly’s (LLY) Inluriyo in combination with Verzenio for adults with ER-positive, HER2-negative breast tumors carrying an ESR1 mutation who have progressed after at least one line of endocrine therapy — extending Inluriyo’s September 2025 monotherapy clearance into combination use. The agency also authorized Guardant Health’s Guardant360 CDx as a companion diagnostic to identify eligible patients. The approval rests on the EMBER-3 trial: in a 159-patient ESR1-mutated subgroup, the combination delivered median progression-free survival of 11.1 months versus 5.5 months for Inluriyo alone — a 47% reduction in the risk of progression (HR 0.53) — with an objective response rate of 35% versus 15%. Tolerability is a watch item: diarrhea occurred in 86% of patients (Grade 3/4 in 9%), and serious adverse reactions were reported in 21%.
Why it matters: ESR1 mutations are a well-known escape route that renders first-line endocrine therapy ineffective, and this approval gives oncologists a data-backed option for precisely the patients who have run out of hormonal options. For Lilly, the combination label expands Inluriyo’s addressable population and deepens its moat in endocrine-driven breast cancer alongside Verzenio, one of its flagship oncology assets — a commercially meaningful extension even though the headline market reaction was muted. The parallel authorization of Guardant360 CDx also underscores how companion diagnostics have become the standard tollbooth for targeted oncology launches. Related reading: our coverage of the latest targeted oncology approval — FDA Approves Lyrfigtu, a New FGFR2-Targeted Drug for Bile Duct Cancer.
What to watch: Lilly’s launch uptake and whether the GI tolerability profile limits real-world use; any payer pushback on combination pricing; overall survival data from EMBER-3 if it matures; and whether the regimen moves earlier into the treatment sequence.
Source:
https://stockti.com/eli-lilly-s-inluriyo-verzenio-combo-gains-fda-nod-shares-steadyAuto-posted by the Bull Lounge news desk.
For an ER+/HER2- patient who has progressed on endocrine therapy, would the 11.1-month progression-free survival benefit outweigh an 86% diarrhea rate for you, or would you wait for overall survival data first?
Log in to vote
